Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment

Annals of Occupational and Environmental Medicine

Robert L Boggs¹  Sarolta Kárpáti⁴  Wenzhi Li¹  Theresa Williams²  Ronald Pedersen²  Lotus Mallbris²  Robert Gniadecki³ 

[1] Formerly of Pfizer Inc., 3921 Glenlake Garden Drive, Raleigh, NC 27612, USA

[2] Pfizer Inc, Collegeville, PA, USA

[3] University of Copenhagen, Copenhagen, Denmark

[4] Semmelweis University, Budapest, Hungary

关键词: Sick days;    Employment;    Etanercept;    Pharmacoeconomics;    Psoriatic arthritis;    Psoriasis;   

Others  :  1084561
DOI  :  10.1186/1471-5945-14-14

 received in 2013-11-01, accepted in 2014-06-04,  发布年份 2014

【 摘 要 】

Background

Psoriasis and psoriatic arthritis (PsA) impair quality of life, including reduction in employment or job duties. The PRESTA (Psoriasis Randomized Etanercept STudy in Patients with Psoriatic Arthritis) study, a randomized, double-blind, two-dose trial, examined the efficacy of etanercept treatment in patients with moderate-to-severe plaque psoriasis and PsA and the main results have been presented previously. This analysis examined employment status, job duties and sick days, pre-defined endpoints in PRESTA, among this patient population.

Methods

Participants (N = 752) were randomized to receive etanercept 50 mg twice weekly (BIW; n = 379) or 50 mg once weekly (QW; n = 373) for 12 weeks by subcutaneous injection. All participants then received open-label etanercept 50 mg QW for 12 additional weeks, while remaining blinded to the randomization. A pharmacoeconomic questionnaire was administered at baseline, week 12 and week 24 of treatment. The questionnaire included employment status and changing job responsibilities and sick time taken due to psoriasis or PsA. The statistical methods included analysis of covariance, t-test, Fisher’s exact test and McNemar’s test. Last-observation-carried-forward imputation was used for missing data.

Results

Employment was at least maintained from baseline to week 24 in both dose groups (56% [BIW/QW] and 60% [QW/QW] at baseline, 61% and 60%, respectively, at week 24). Among employed participants, the proportion of patients whose job responsibilities changed due to PsA decreased significantly from baseline to week 24 (17–23% to 5–8%; p < 0.01). Similar results were seen with job responsibility changes due to psoriasis (11–14% to 4%; p < 0.01). The number of monthly sick days also decreased from baseline to week 24 (2.4 days for both treatment groups to 0.7 (BIW/QW) and 1.1 (QW/QW); p ≤ 0.03 for each). No significant differences between the treatment groups were observed for any economic endpoint at any time point.

Conclusions

For patients with moderate-to-severe plaque psoriasis and PsA, etanercept treatment resulted in reducing job responsibility changes due to disease and in reducing sick time. Effective treatment of psoriasis and PsA may reduce missed work days.

【 授权许可】

   
2014 Boggs et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Gladman DD: Psoriatic arthritis. Dermatol Ther 2004, 17:350-363.
• [2]Gottlieb AB, Chao C, Dann F: Psoriasis comorbidities. J Dermatol Treat 2008, 19:5-21.
• [3]Mease P: Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology. Curr Rheumatol Rep 2006, 8:348-354.
• [4]Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T: Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004, 9:136-139.
• [5]Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PC, Chimenti S, Lotti T, Schäfer G: European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006, 155:729-736.
• [6]Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ: Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004, 51:704-708.
• [7]Zachariae H, Zachariae R, Blomqvist K, Davidsson S, Molin L, Mørk C, Sigurgeirsson B: Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 2002, 82:108-113.
• [8]Radtke MA, Reich K, Blome C, Rustenbach S, Augustin M: Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 2009, 23:683-691.
• [9]Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, Estojak J, Molta CT, Freundlich B: Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010, 340:c147.
• [10]Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, Boggs R, Zbrozek AS: Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol Venereol 2012, 26:1436-1443.
• [11]Prinz JC, Fitzgerald O, Boggs RI, Foehl J, Robertson D, Pedersen R, Molta CT, Freundlich B: Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial. J Eur Acad Dermatol Venereol 2011, 25:559-564.
• [12]Short-Term Labour Market Statistics: Employment Rate http://stats.oecd.org/Index.aspx?QueryId=38900 webcite
• [13]Gladman DD, Bombardier C, Thorne C, Haraoui B, Khraishi M, Rahman P, Bensen W, Syrotuik J, Poulin-Costello M: Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial. J Rheumatol 2011, 38:1355-1362.
• [14]Wallenius M, Skomsvoll JF, Koldingsnes W, Rødevand E, Mikkelsen K, Kaufmann C, Kvien TK: Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis 2009, 68:685-689.
• [15]Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR: The negative impact of psoriasis on the workplace. J Dermatol Treat 2006, 17:24-28.
• [16]Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH: Validity of the work productivity and activity impairment questionnaire–general health version in patients with rheumatoid arthritis. Arthritis Res Ther 2010, 12:R177. BioMed Central Full Text